google.com, pub-3677220355429816, DIRECT, f08c47fec0942fa0
top of page
Search

New Lupus Drug 2025 Enpatoran Shows Promise in Phase II Trial—Despite Missing Main Goal.

Updated: Jun 20

Woman with long red hair and butterflies
A vivid depiction of a young woman with cascading red hair, encircled by butterflies, representing resilience and transformation in confronting lupus.

Why the Enpatoran Lupus Drug Trial May Still Be a Win for Patients


🌟 Novel Lupus Drug Clears Phase II Hurdle — Trial of Enpatoran “missed” primary endpoint, but in a good way

A Phase II study of new lupus treatment 2025 enpatoran, a first‑in‑class oral TLR7/8 inhibitor, has shown encouraging results in patients with systemic lupus erythematosus (SLE)—despite not formally meeting its primary endpoint. Presented last week in Barcelona, the data suggest the drug’s benefits, particularly in cutaneous lupus, may justify moving forward into Phase III.

🧪 What was the trial?

The WILLOW study—sponsored by Merck KGaA/EMD Serono—enrolled over 450 SLE and cutaneous lupus (CLE) patients. Participants were randomized to either 25 mg, 50 mg, or 100 mg of enpatoran twice daily or placebo plus standard-of-care. The primary endpoint: a dose‑response trend in the BICLA (British Isles Lupus Assessment Group‑based Composite Lupus Assessment) at Week 24 in Cohort B (patients with moderate/severe active SLE) ground.news+6emdserono.com+6businesswire.com+6.

🎯 Why missing the primary endpoint isn’t a failure

While the trial did not achieve the required dose-response curve for BICLA in Cohort B, secondary outcomes painted a brighter picture. In a prespecified subgroup of patients with active cutaneous disease (CLASI‑A ≥ 8):

Additionally, other subgroups (such as high corticosteroid or interferon gene signature patients) also showed “higher and relevant” response rates fiercebiotech.com+2emdserono.com+2businesswire.com+2.

🧬 Why targeting skin manifestations matters

  • About 70–80% of lupus patients struggle with cutaneous symptoms—itching, rash, scarring—that significantly impact quality of life businesswire.com.

  • In Cohort A (CLE or SLE with rash), enpatoran met its primary endpoint at Week 16, with up to 91% achieving CLASI‑50, and ~60.9% achieving CLASI‑70—all well tolerated hcplive.com+5biospace.com+5emdserono.com+5.

🛡️ Safety & tolerability

Enpatoran was well tolerated, with similar rates of treatment‑emergent adverse events (~60–64%) between active drug and placebo. The most common were mild infections—no concerning safety signals were observed emdserono.com+1businesswire.com+1.

🔍 So, what’s next?

Despite the primary endpoint miss, Merck believes the strong skin-related benefits and consistent subgroup signals justify advancing to Phase III discussions with regulators. According to Fierce Biotech:

“Merck KGaA has shed more light on the failure … while pointing to secondary endpoint readouts as proof that the candidate still deserves a shot at seeking approval.” ground.news+2fiercebiotech.com+2clinicaltrialsarena.com+2

Regulatory dialogue is underway to identify the best path forward—potentially a larger Phase III trial focusing on high‑need patient groups, like those with active cutaneous disease biospace.com+4emdserono.com+4businesswire.com+4.

✅ Bottom Line for Patients & Providers

  • 🆕 First-in-class: Enpatoran targets TLR7/8, a new mechanism modulating immune-driven inflammation.

  • 💊 Promising skin results: High rates of CLASI improvement in patients with active rash.

  • 🧾 Good tolerability: Side effects aligned with placebo — primarily mild infections.

  • 🔜 Phase III ahead? Merck is initiating regulatory discussions to define next steps.

For lupus patients, especially those struggling with persistent skin symptoms, enpatoran could represent a meaningful new treatment option in the coming years—if larger trials confirm its promise.

📚 Sources


 
 
 

Comments

podcast-directory-5e9cdf1bc9d1a88d9302a5

Subscribe

Pandora Podcast

©2018 by My Story Living With Lupus. Proudly created with Wix.com

bottom of page